Tirzepatide is a novel drug that works as an agonist of both GLP-1 and GIP. How does this compare to semaglutide, a GLP-1 agonist? Join us as we discuss the SURPASS-2 trial, and compare the drugs’ mechanisms of action, effect on hemoglobin A1c, impact on weight, and overall clinical outcomes.

This journal club dissects an article from The New England Journal of Medicine – Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. 

Upon successful completion of this application-based course, pharmacists and pharmacy students should be able to:
1. Describe the mechanism of action of tirzepatide
2. Compare and contrast tirzepatide with semaglutide
3. Discuss clinical trial data on tirzepatide’s effect on hemoglobin A1c at various doses as compared to semaglutide
4. Discuss the impact of tirzepatide on patient weight
5. Develop a conclusion for tirzepatide’s role in patient-centered diabetes care based on a clinical trial

Ellen Jones, PharmD
Assistant Professor
Harding University College of Pharmacy

Ellen Jones has no relevant financial relationships to disclose. 

To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read:

Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PMID: 34170647.

*CEimpact provides you with two (2) opportunities to complete the exam. If there are two failed attempts, the participant will not receive CPE credit.

Fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: April 13, 2022
Planned Expiration Date: April 13, 2025  

RV2-1.24